Recent Updates
Recently added Catalysts
UTHR Positive Sentiment

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: United Therapeutics Corporation will participate in two investor conferences in London. CFO James Edgemond is scheduled to provide updates during fireside chat sessions. The UBS Global Biopharma Conference is on November 16, 2026, and the Jefferies Global Healthcare Conference follows on November 17, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • United Therapeutics will present at two major investor conferences.
  • James Edgemond will provide updates during the sessions.
  • The conferences are well-regarded in the biopharma industry.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
5.1%
average across 11 past catalysts
Lead asset
GGTA1 KO Thymokidney
Phase 2 · ESRD (End-Stage Renal Disease)

Full Press Release Details

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview and update during fireside chat sessions at two upcoming investor conferences in London. UBS Global Biopharma Conference on Monday, November 16, 2026, from 10:00 a.m. to 10:30 a.m., GMT. Jefferies Global Healthcare Conference on Tuesday, November 17, 2026, from 2:00 p.m. to 2:25 p.m

Frequently Asked Questions

Who will represent United Therapeutics at the conferences?

CFO James Edgemond will provide an overview and updates.

When is the UBS Global Biopharma Conference?

It is scheduled for November 16, 2026, from 10:00 a.m. GMT.

What is the date of the Jefferies Global Healthcare Conference?

The conference will take place on November 17, 2026.

What type of session will James Edgemond participate in?

He will participate in fireside chat sessions.

ShareAdd on Google
Tags: UTHR United Therapeutics investor conferences James Edgemond UBS Global Biopharma Jefferies Global Healthcare
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$3536M liquidity · $0M/mo burn
Low dilution risk
Lead asset
GGTA1 KO ThymokidneyPhase 2
ESRD (End-Stage Renal Disease) →

Catalyst track record

+29%
best trade around UTHR's most recent catalyst

Peak hindsight return over a 120-day window, across 11 tracked FDA/PDUFA catalysts for UTHR.

See every catalyst's timing & PoA →